Bio Pharma Dive
MAY 31, 2022
BioMarin now expects to resubmit its approval application to the FDA by the end of September, the latest regulatory setback for the company's closely watched treatment.
World of DTC Marketing
JUNE 3, 2022
The continued emphasis on digital health is overrated but digital health will become an integral part of total patient care. To become a vital part of patient care, digital health providers need to provide the medical community with studies that show their value to patient outcomes. The rapid advancement in the digital healthcare field brings many advantages and a few problems that shouldn’t be ignored.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 1, 2022
The technology behind virtual reality is rapidly advancing, allowing developers to create entire 3D hospitals for training purposes. In this article, Ben Hargreaves looks at how VR headsets are being used to better educate both healthcare professionals and the general public. Digital healthcare solutions are being talked about with increasing frequency.
BioPharma Reporter
JUNE 2, 2022
Interest in vaccines against monkeypox is growing as the outbreak spreads around the world. The arsenal includes existing smallpox vaccines and potential new monkeypox specific mRNA vaccines.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
JUNE 1, 2022
Positive Phase 2 results could help boost company executives' arguments that the drug, called deucravacitinib and under FDA review in psoriasis, will become a top-seller.
World of DTC Marketing
JUNE 1, 2022
Five of America’s largest health insurers reported more than $11bn in profits in the second quarter – a decline from the same period last year when the Covid-19 pandemic helped drive sky-high profits yet they are having more of a say on patients’ treatments even when HCPs disagree. A vibrant 83-year-old man hurt his back while gardening. His neurologist diagnosed the problem as a disk issue that could be fixed with surgery.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioPharma Reporter
JUNE 1, 2022
With mRNA tech achieving major success against COVID-19, the initiation of trials into vaccination against HIV is creating discussion amid a potential breakthrough in the prevention of the disease.
Bio Pharma Dive
JUNE 2, 2022
Backed by $200 million in funding and led by biotech veteran Samantha Truex, Upstream is developing a clinical-stage inflammatory disease drug acquired from Astellas last year.
World of DTC Marketing
MAY 31, 2022
There’s quite a debate in the CPG world about the investment in digital marketing. While some are increasing their digital budgets, does a pancake syrup company need to spend much money? However, with pharma brands, online is essential to a successful marketing strategy. According to Google search statistics, “health” and “wellness” topics are among the top searches.
Pharma Times
MAY 31, 2022
‘Act4Biosimilars’ will improve patient access and increase adoption in over 30 countries by 2030
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharma Mirror
JUNE 2, 2022
SINGAPORE, Azelis, a leading innovation service provider in the specialty chemicals and food ingredients industry, announces the opening of its Regional Innovation Center (RIC) for Food & Nutrition (F&N) in Singapore, further demonstrating the Group’s commitment to continuously invest in its innovation capabilities. The RIC will generate a wealth of possibilities for food innovation towards healthier and tastier solutions through pioneering, ready-to-use formulations with advance
Bio Pharma Dive
MAY 31, 2022
The deal is the second acquisition for GSK since April and gives the company access to an experimental shot that’s meant to surpass new products from Pfizer and Merck & Co.
Worldwide Clinical Trials
MAY 31, 2022
By: Kerri Padgett, Courageous Parents Network. This year, I will celebrate the life of my son, Kai, for the 10th time since his passing from hypothalamic optic glioma at the age of two. I feel immense gratitude for the support we received during his cancer journey, but there are also moments when I wish I’d had more support. I know there are many families out there needing more, too.
Pharma Times
JUNE 1, 2022
The drug is used to treat seizures caused by this rare syndrome that is a form of epilepsy
pharmaphorum
MAY 31, 2022
Sanofi and Regeneron should hear from the FDA in the autumn whether it will approve their blockbuster immunology drug Dupixent as a therapy for rare skin disease prurigo nodularis (PN). The US regulator has granted Dupixent (dupilumab) a six-month priority review in PN and is due to deliver a verdict by 30 September, offering patients hope of a first-approved therapy for the highly-debilitating disease.
Bio Pharma Dive
JUNE 3, 2022
Dive Brief: Bristol Myers Squibb is buying biotech Turning Point Therapeutics, announcing Friday a $4.1 billion deal that will give the pharmaceutical company an experimental drug that targets mutations found in lung cancer and other solid tumors. The deal values Turning Point at $76 a sh.
BioPharma Reporter
JUNE 1, 2022
A well-funded and appropriately rewarded biotech ecosystem is needed for the next generation of antibacterials to reach the clinic and beyond, according to BIOâs State of Innovation in Antibacterial Therapeutics report.
Pharma Times
MAY 31, 2022
Antibody addresses high unmet medical need in rapidly growing kidney transplant market
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
MAY 30, 2022
The American Society of Clinical Oncology, or ASCO, conference is just around the corner, but one subgroup of cancer researchers just had their own gathering, as breast cancer researchers came together in person for the first time since the start of the pandemic at the ESMO Breast Cancer congress. pharmaphorum sat down with Sunil Verma, global head of oncology, medical, at AstraZeneca, to discuss three studies that were presented at the show, which demonstrate a few of the ways oncology is advan
Bio Pharma Dive
MAY 31, 2022
Evrysdi, the only oral drug for the neurodegenerative disorder, can now be used to treat babies younger than 2 months who have been identified through newborn screening.
BioPharma Reporter
JUNE 1, 2022
From the future of RNA to the applications of AI in drug development, hereâs 10 of the top sessions for biopharma pros at BIO in San Diego this month.
Pharma Times
MAY 30, 2022
The injection is given in combination with chemotherapy and administered once every three weeks
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
MAY 30, 2022
In future, blood samples may be taken by an autonomous robot rather than a healthcare professional – if Dutch developer Vitestro can get its prototype approved for marketing. Vitestro’s blood drawing (phlebotomy) robot is designed to offer a solution to what the company says is a growing shortage of healthcare personnel, coupled with rising demand for blood tests with billions carried out every year worldwide.
Bio Pharma Dive
JUNE 2, 2022
Severino left the pharma company in April after eight years as its chief scientist and then president. He'll lead Tessera Therapeutics, a well-funded genetic medicine startup.
BioPharma Reporter
MAY 31, 2022
Eli Lilly and Company plans to expand its manufacturing footprint in Indiana by investing $2.1bn in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.
Pharma Times
MAY 30, 2022
NRG Therapeutics announces multi-million Innovate UK Award to develop treatments for Parkinson’s and motor neurone disease
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JUNE 1, 2022
GlaxoSmithKline is due to complete the split from its consumer health decision – now renamed Haleon – next month, with a listing for the new company on the London Stock Exchange set for 18 July. GSK said it has now filed a prospectus for the submission of Haleon’s ordinary shares to the stock market with the Financial Conduct Authority (FCA), and is awaiting approval for the move.
Bio Pharma Dive
JUNE 3, 2022
The agency said it wanted more time to assess additional clinical trial data submitted by Amylyx, and set a new decision date of Sept. 29 for the closely watched treatment.
BioPharma Reporter
MAY 30, 2022
The company will provide its current and future portfolio of patented medicines to 45 lower-income countries, but the move is not without controversy.
BioSpace
JUNE 1, 2022
AstraZeneca CEO Pascal Soriot has been knighted in the Queen's Birthday Honours for his contribution to life sciences and leadership during the COVID-19 pandemic.
Expert insights. Personalized for you.
344 
Let's personalize your content